MUSCLE & NERVE is a prestigious journal dedicated to the exploration and advancement of knowledge in the fields of neurology, cellular and molecular neuroscience, and physiology. Published by Wiley, this journal has been a crucial resource for researchers and practitioners since its inception in 1978, with an impressive convergence of studies anticipated through 2024. With an Impact Factor reflecting its relevance and influence—ranking in the Q2 and Q3 quartiles across multiple categories, including clinical neurology and medical physiology—MUSCLE & NERVE offers a rigorous peer-reviewed platform for groundbreaking research. It holds a respected position in Scopus rankings, illustrating its commitment to excellence and innovation in medicine and neuroscience. As a non-open access journal, it provides valuable resources for professionals seeking to further their understanding of neuromuscular physiology and related disciplines. The journal aims to foster dialogue and disseminate knowledge that advances the field, making it an indispensable tool for academics and clinicians alike.

Degenerative Neurological and Neuromuscular Disease is a distinguished academic journal published by DOVE MEDICAL PRESS LTD, focusing on the latest advancements in the field of neurology and neuromuscular disorders. With a commitment to disseminating high-quality research, the journal aims to provide a critical platform for researchers, healthcare professionals, and students to share and engage with groundbreaking studies that advance our understanding of degenerative conditions affecting the nervous system. Although the journal's impact factor and h-index are currently not available, its open access model ensures that the valuable findings published within are accessible to a global audience, thereby fostering collaboration and innovation in neurological health. The journal's address is PO BOX 300-008, Albany, Auckland 0752, New Zealand, reflecting its international relevance and commitment to advancing the field of neurology. As the understanding of neurodegenerative diseases and neuromuscular challenges continues to evolve, Degenerative Neurological and Neuromuscular Disease serves as an essential resource for anyone dedicated to improving patient outcomes and advancing scientific knowledge.

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.

NEUROMUSCULAR DISORDERS is a premier academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest research and developments in the fields of neurology, genetics, and pediatric health. With an ISSN of 0960-8966 and an E-ISSN of 1873-2364, this journal has established a significant presence since its inception in 1991, and it continues to contribute to the scientific community with its impactful findings and reviews. The journal boasts a commendable impact factor, reflected in its placement in the Q2 category for Clinical Genetics and Neurology, as well as its positioning in the top tier Q1 for Pediatrics, Perinatology and Child Health according to the latest quartile assessments. With Scopus rankings such as Rank #71/330 in Pediatrics and Rank #51/99 in Clinical Genetics, NEUROMUSCULAR DISORDERS is recognized for its contribution to advancing knowledge in neuromuscular diseases. The journal is essential for researchers, clinicians, and students interested in the intricate relationship between genetics and neurological disorders, providing valuable insights that drive innovation and improve patient care.

Molecular Genetics and Metabolism Reports is a peer-reviewed, open-access journal published by Elsevier that has been serving the scientific community since its inception in 2014. With an E-ISSN of 2214-4269, this journal focuses on publishing high-quality research in the rapidly evolving fields of *molecular genetics*, *endocrinology*, and *molecular biology*. Despite its relatively short history, the journal has established itself within the academic landscape, evidenced by its categorization in the 2023 Q3 quartile rankings for its respective fields, including genetics and molecular biology. Researchers and students are encouraged to disseminate their findings, as the open-access model provides unrestricted access to vital research, facilitating knowledge sharing and collaboration across disciplines. The journal aims to promote innovative studies that explore the genetic and metabolic underpinnings of human health, making it an essential resource for professionals seeking to stay abreast of the latest advancements and trends in molecular genetics and metabolism.

Therapeutic Advances in Urology is a distinguished, peer-reviewed journal published by SAGE Publications Ltd, dedicated to disseminating groundbreaking research and advancements in the field of urology. With an impressive impact factor and classified in the Q2 category for Urology as of 2023, this journal plays a critical role in advancing knowledge and clinical practices related to urological diseases and therapies. Since its establishment in 2009, the journal has transitioned to an Open Access format as of 2019, ensuring that vital research findings are freely available to researchers, healthcare professionals, and students worldwide. The journal is ranked #44 out of 120 in the Medicine - Urology category within Scopus, reflecting its commitment to high-quality, impactful scholarship. Whether you are seeking to keep abreast of the latest therapeutic innovations or contribute to the evolving discourse in urology, Therapeutic Advances in Urology is an essential resource for those passionate about improving patient outcomes and advancing clinical practices.

JOURNAL OF INHERITED METABOLIC DISEASE, published by Wiley, stands at the forefront of research within the fields of genetics and clinical genetics. With an impressive impact factor reflected in its prestigious Q1 category rankings in both Genetics and Clinical Genetics, this journal provides a vital platform for groundbreaking studies and discoveries in inherited metabolic disorders. Since its inception in 1978 and continuing through 2024, it has consistently featured high-quality peer-reviewed articles that advance understanding and treatment options in this critical area of medicine. Researchers and professionals interested in the genetic underpinnings of metabolic diseases will find the journal's contributions invaluable for both their practical applications and theoretical advancements. Although it does not currently offer open access options, subscribers and readers who access the journal will benefit from rich, impactful content and findings that could influence clinical practices and future research initiatives in the field.

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

Discover Oncology, published by SPRINGER, is an influential journal based in Germany that focuses on the latest advancements in the fields of oncology and endocrinology. With an evolving scope that spans critical research from 2021 to 2024, this journal aims to provide a platform for innovative ideas and research findings that can significantly impact clinical practices. Although it currently holds a Q3 ranking in several Cancer Research and Endocrine category quartiles, its commitment to open access ensures that relevant knowledge is available to a wider audience, facilitating the exchange of ideas among researchers, professionals, and students. As evidenced by its growing presence in various medical spheres, including a Q2 ranking in Endocrinology and Diabetes, the journal plays a crucial role in advancing multidisciplinary research that integrates oncology with broader biological and medical parameters. For those in the field, Discover Oncology serves as both a resource and a community hub, encouraging collaboration and exploration of emerging findings that can lead to novel therapeutic approaches.